In binge-eating disorder, behavioral weight loss therapy (BWL) with or
Bupropion and naltrexone is a combination medicine used to help manage weight in
Introduction: Binge eating disorder (BED) is associated with obesity and major depressive disorder (MDD)
While the lifetime prevalence of binge eating disorder in the USA is estimated at 2
This is an acute treatment comparing behavioral weight loss alone or in combination with naltrexone/bupropion medication
Adult patients with BED with co-occurring obesity who have good responses to acute treatment with naltrexone/bupropion should be offered maintenance treatment with naltrexone Purpose: Binge eating disorder (BED) has a considerable clinical relevance by virtue of its high numerous psychiatric and medical comorbidities; among the latter, the most frequent is obesity
Studies in obese populations have demonstrated a significant reduction in binge
you have used a monoamine oxidase inhibitor (MAOI) within the previous 14 days
Drug Dosage Dose form Cost*; Naltrexone/bupropion (Contrave) 8/90 mg per day, increasing over four weeks to 16/180 mg twice daily: 8/90-mg extended-release tablet This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity
1 kg/m2) with binge-eating disorder
Binge-eating disorder (BED) is the most common specific eating disorder, and the estimated lifetime global prevalence is between 0
However, bupropion did not improve binge eating, food craving or depressive symptoms compared to placebo
The study concluded that BWL + naltrexone-bupropion was superior to the rest of the groups in providing weight loss in obese subjects and helping patients achieve remission from binge eating episodes
Naltrexone/bupropion SR (NB) showed good efficacy and tolerability for treating OBE and altered eating behaviors associated with binge